Neuromed Pharmaceuticals Ltd.

Neuromed Pharmaceuticals Ltd.

NeuroMed Pharmaceuticals Ltd. is a privately held Canadian biopharmaceutical company located in Vancouver, Canada. The Company is focused on the development of novel small molecule drugs designed to block neuronal calcium channels for the purpose of treating neurological diseases, with the initial emphasis on pain, stroke and anxiety.

NeuroMed has fast tracked the drug discovery process by coupling rational drug design with in-house direct biological assays to identify highly selective drug candidates for their target, in this case calcium channels. Its drug candidates block the N-type calcium channels preventing an unwanted influx of calcium into a cell. This influx is the cause of over-reactive pain signaling as well as neuronal cell death leading to disabilities following a stroke. In addition to the therapeutic benefits, NeuroMeds drugs should be non-addictive and avoid other side effects of current pain medication.

The Company has raised $74 million Cdn to date.

NeuroMeds priority drug candidates will play an important role in very significant markets with large unmet needs: pain, anxiety and stroke. The initial target market is for moderate to severe pain, including neuropathic and cancer pain, and as such will be competing against centrally acting analgesics including opioids. Many people suffering chronic pain take opioids with resulting side effects. In 2000 there were 85 million chronic and 141 million acute pain sufferers in the US. The worldwide market for NSAIDs, narcotics and antimigraines was $21.6 billion in 2000, with a projected market of $29.7 billion in 2007. Stroke is the third leading cause of death in the US, Canada, Japan and Europe. By 2005, the market for stroke drugs is expected to grow to $3.8 billion. The worldwide anxiety market was $2 billion in 1999.

NeuroMeds second major development program is focused on the T-type calcium channel which is implicated in epilepsy and cardiovascular disease.

NeuroMed has attracted and retained highly skilled people. Our in-house teams include molecular biology, chemistry, electrophysiology, drug development and all areas of management. We have complemented our resources by hiring consultants to assist in fast tracking the drug development process and implementing NeuroMeds clinical plans.

In November 1998, the Company completed its seed financing round totaling $5 million led by MDS Capital Corp. In December 2000 and March 2001, NeuroMed closed its B round of financing of $21 million. The major investors in the round were Business Development Bank of Canada, GrowthWorks Capital, MDS Capital, Trian Equities, RBC Capital Partners and a number of boutique funds and high net worth individuals. The Company closed it's C Round financing at US $32 million - Canada's largest venture financing of the year. In March 2006, Neuromed closed its Series D round of financing at US $25 million, thanks to a syndicate of top tier of US and Canadian investors.

Company Details

Year Established: 1995

Company Information

Bruce Colwill
Title: Vice President
Telephone: (604) 909-2530
Fax: (604) 909-2538
Email: Click Here

Terrance Snutch
Title: Vice President
Telephone: (604) 909-2530
Fax: (604) 909-2538
Email: Click Here

Chris Gallen
Title: Chief Executive Officer
Telephone: (604) 909-2530
Fax: (604) 909-2538
Email: Click Here

Products

Pharmaceuticals

Services